ÂÜÀòÂÒÂ×

Michael Goldstein, M.D., is President and Chief Medical Officer at Aurion Biotech, a clinical stage cell therapy company where he leads the clinical development, clinical operations, medical affairs, program management, manufacturing and quality teams. Before Aurion Biotech, Dr. Goldstein was President, Ophthalmology and Chief Medical Officer at Ocular Therapeutix (Nasdaq: OCUL), a developer of longer-duration therapies for patients with ophthalmic diseases. Previously, he was chief medical officer for AGTC and Eleven Biotherapeutics. He is also an assistant professor at Tufts University School of Medicine and was co-director of the Cornea, External Disease service at Tufts University/ New England Eye Center and residency director at Tufts University/New England Eye Center. For over 20 years, Dr. Goldstein has been actively involved with clinical research and biotechnology consulting to small and large companies for multiple disease indications in the front and back of the eye, including biologics, gene therapy, and small molecules. Dr. Goldstein was president of the Massachusetts Society of Eye Physicians (MSEPS) from 2011-2013 and has been a member of the MSEPS executive board since 2004.

Dr. Goldstein earned his MD at Northwestern University Medical School, conducted his postgraduate residency training at Boston University Medical Center and fellowship training in cornea/external diseases at the University of Pittsburgh Eye and Ear Institute.

He earned his MBA from the Kellogg Graduate School of Management at Northwestern University and his BA in Political Economy from Williams College.